Active learning identifies a protoglobin variant with 99% yield and cis-selective cyclopropanation
An iterative machine-learning campaign engineered the protoglobin from Pyrobaculum arsenaticum (ParPgb) for non-native cyclopropanation of 4-vinylanisole. After two model-guided rounds following an initial library screen, variant MPFDY gave 99% total cyclopropane yield and a 14:1 cis:trans ratio in the reported assay, compared with a parent variant that produced about 40% yield and favored trans product. The result demonstrates a specific sequence combination with improved yield and stereoselectivity in this enzyme scaffold.
Technology: ALDE (Active Learning-assisted Directed Evolution), using a bootstrapped deep-neural-network ensemble and Thompson sampling
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: After two model-guided rounds following an initial library screen, variant MPFDY gave 99% total cyclopropane yield and a 14:1 cis:trans ratio in the reported assay, compared with a parent variant that produced about 40% yield and favored trans product.
- Still unknown: Cyclopropanation is an established non-native enzyme reaction class; the study's distinct result is the ALDE-guided ParPgb sequence and its measured product yield/selectivity. The 99% yield and 14:1 ratio are study assay results, not evidence of industrial process readiness. The study is a single enzyme-engineering campaign.
- AI role: ALDE trained on measured sequence–yield data, quantified model uncertainty, and selected variants across two iterative rounds in a five-residue, 3.2-million-sequence design space. Experimental screening measured product yield and stereoselectivity; the model-guided variants included MPFDY, whose combined mutations improved the targeted cis-product objective where tested single mutations and their naive recombinations did not.
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11739421/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 186 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.